logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics teams up with Winclove Probiotics for psoriasis supplement

SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman caught up with Proactive London's Andrew Scott following the news they've agreed a deal with Dutch firm Winclove Probiotics to develop a food supplement to combat psoriasis.

The pair plan to carry out a human study on mild to moderate sufferers of the skin condition, which will take between 12 and 18 months ahead of commercialisation and launch of the probiotic.

Quick facts: SkinBioTherapeutics PLC

Price: 26.5 GBX

AIM:SBTX
Market: AIM
Market Cap: £33.94 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics CEO hails 'significant scientific milestone' with...

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive's Andrew Scott soon after updating investors on the progress of its cosmetic skincare programme and plans for a psoriasis food supplement trial. Sederma, its partner in the cosmetics programme and a division of Croda...

1 week, 5 days ago

2 min read